- Home
- EVMN vs ATXS Comparison
EVMN vs ATXS Comparison
Compare EVMN & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | ATXS |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 628.9M | 732.4M |
| IPO Year | 2025 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EVMN | ATXS |
|---|---|---|
| Price | $17.01 | $12.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 6 |
| Target Price | ★ $39.33 | $24.33 |
| AVG Volume (30 Days) | 189.2K | ★ 1.3M |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,000,000.00 | $706,000.00 |
| Revenue This Year | $89.43 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 160.00 | N/A |
| 52 Week Low | $13.89 | $3.56 |
| 52 Week High | $24.03 | $13.29 |
Technical Indicators
Market Signals| Indicator | EVMN | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 61.19 |
| Support Level | N/A | $12.64 |
| Resistance Level | N/A | $13.04 |
| Average True Range (ATR) | 0.00 | 0.20 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 61.54 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.